Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity

Area of Science:

• Nephrology
• Oncology
• Pharmacology

Background:

• Dasatinib, a tyrosine kinase inhibitor, is associated with potential nephrotoxicity.
• Glomerular injury is a concern in patients undergoing tyrosine kinase inhibitor therapy.

Purpose of the Study:

• To investigate the incidence of proteinuria in patients treated with dasatinib.
• To identify risk factors associated with dasatinib-induced glomerular injury.

Main Methods:

• Assessed glomerular injury using urine albumin-creatinine ratio (UACR) in 82 chronic myelogenous leukemia patients on tyrosine kinase inhibitors for at least 90 days.
• Compared UACR levels between dasatinib users and users of other tyrosine kinase inhibitors.
• Analyzed dasatinib plasma pharmacokinetics and correlated drug concentrations with proteinuria development.
• Included a case study of a patient with nephrotic-range proteinuria on dasatinib.

Main Results:

• Dasatinib users (n=32) exhibited significantly higher UACR levels (median 28.0 mg/g) compared to other tyrosine kinase inhibitor users (n=50, median 15.0 mg/g; P < 0.001).
• 10% of dasatinib users showed severely increased albuminuria (UACR >300 mg/g), versus none in the other group.
• Average dasatinib plasma concentrations positively correlated with UACR (ρ=0.54, P=0.03) and treatment duration (P=0.003).
• Kidney biopsy in the case study revealed glomerular damage that resolved upon dasatinib cessation.

Conclusions:

• Dasatinib exposure is linked to a significantly higher incidence of proteinuria compared to other tyrosine kinase inhibitors.
• Elevated dasatinib plasma concentrations are a key risk factor for developing proteinuria during treatment.